Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01991808
Other study ID # UPCC 26812
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2013
Est. completion date December 8, 2016

Study information

Verified date November 2019
Source Abramson Cancer Center of the University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study of DCE MR imaging to detect vascular changes in the vagina during and after radiotherapy n patients receiving adjuvant brachytherapyfor cervical or endometrial cancer.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date December 8, 2016
Est. primary completion date December 8, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Must be 18 years of age.

- Must have histologically confirmed carcinoma of the cervix, carcinoma or carcinosarcoma of the uterus.

- Subjects are receiving intracavitary brachytherapy.

- ECOG performance status of 0-2.

- Creatinine clearance 30.

Exclusion Criteria:

- Subjects with an inability to tolerate MR imaging (i.e. claustrphobia)

- Study subjects who have contraindication to MRI scanning such as but not limited to subjects with pacemakers, metal fragments in the eye or certain metallic implants.

- Patients who do not speak or read English.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radiotherapy


Locations

Country Name City State
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events 2 years